Modified cell vesicles trigger 'lipid counterstorm' against lung inflammation in mice

Scientists have identified a novel approach to combating severe respiratory inflammation using modified cell-derived vesicles that trigger a protective "lipid counterstorm." In experiments conducted on mice, these specially treated extracellular vesicles significantly reduced lung inflammation caused by conditions such as acute respiratory distress syndrome, offering hope for new treatments for a range of inflammatory diseases. The research, led by a team from the University of Osaka and other institutions, focused on extracellular vesicles, small, membrane-bound particles released by cells that carry genetic material, proteins, and lipids. These vesicles are already being explored for their potential in treating various medical conditions due to their ability to influence cellular behavior. However, the team discovered that modifying these vesicles with a specific enzyme dramatically enhances their effectiveness. The researchers used liver cell-derived extracellular vesicles and treated them with secreted phospholipase A2 (sPLA2), creating what they call sPLA2-reacted extracellular vesicles, or SPLEVs. When injected into mice suffering from acute respiratory distress syndrome, the SPLEVs demonstrated a marked reduction in lung inflammation. The treatment resulted in fewer immune cells infiltrating the lungs and a significant decrease in cytokine production, which are key drivers of the damaging immune responses seen during severe infections like those associated with COVID-19. The mechanism behind the SPLEVs’ success appears to involve direct interaction with lung epithelial cells. Unlike conventional extracellular vesicles, which primarily target macrophages, the SPLEVs specifically engage with the lung’s inner lining. This interaction prompts the production of large quantities of protective lipids, leading the researchers to coin the term "lipid counterstorm" to describe the process. This lipid surge effectively neutralizes the harmful effects of a cytokine storm, a condition characterized by an overactive immune response that can lead to organ failure and death. Beyond respiratory conditions, the SPLEVs showed promise in treating other inflammatory disorders. In additional studies, the modified vesicles provided benefits in models of sepsis, coagulopathy, liver injury, colitis, and pneumonia. The observed increase in lysophosphatidylglycerols after SPLEV treatment suggests that these vesicles might serve as a foundation for developing cost-effective, cell-free therapies in the future. The discovery builds on growing interest in extracellular vesicles as potential therapeutic agents. Mesenchymal stem cell-derived extracellular vesicles had previously drawn attention for their anti-inflammatory properties. However, the current study highlights the superior efficacy of liver cell-derived vesicles when enhanced with sPLA2. Lead researcher Shunya Nakayama emphasized that the findings open up new avenues for treating cytokine storms, which are linked to numerous serious illnesses. Senior author Ai Kotani noted that the SPLEVs’ selective targeting of lung tissues was unexpected and represents a crucial insight into how these modified vesicles function. The team’s work underscores the importance of understanding how different types of extracellular vesicles interact with specific organs and tissues, which could guide the development of more effective and targeted treatments. The research has been published in Science Advances, a reputable journal that covers cutting-edge scientific discoveries. The study provides detailed data supporting the efficacy of SPLEVs in reducing inflammation and outlines the potential applications of this technology in human medicine. While clinical trials in humans are still needed, the preliminary results suggest that SPLEVs could become a valuable addition to existing treatment strategies for severe inflammatory conditions.